|
Website:
http://www.gwpharm.com
Phone: +44 1980 557000 |
Address:
Porton Down Science Park
Salisbury, Wiltshire SP4 0JQ |
Company Description
GW Pharmaceuticals PLC. The Group's principal activity is developing a range of new medicines based on cannabis and other controlled drugs. The Group's lead programme is the development of a portfolio of cannabinoid medicines, including Sativex, to meet patient needs in a wide range of therapeutic indications. The principal initial target areas are MS spasticity, neuropathic pain, neuropathic pain in MS and cancer pain. The Group's research also includes the use of other controlled drugs in conjunction with its proprietary secure drug dispensing technology. The Group operates predominantly in the United Kingdom. Develops a range of new medicines based on cannabis and other controlled drugs
Key People
| Executive Chairman | Dr. Geoffrey W. Guy |
| Deputy Chairman | James Noble |
| Executive Managing Director | Justin D. Gover |
| Executive Director Finance | David Kirk |
| Secretary | Jonathan M.E. Laughton |
Related Business Topics
Breaking News
Reuters UK - November 25, 2009 2:22 AM
Pharma posts FY profit Reuters adsrc 'reuters.co.uk/finance/deals/regulatory/article;' ( typeof(AD_TRACKER) 'undefined' AD_TRACKER.globalAdSrcType null ) ((typeof (hideAllAds) 'undefined' hideAllAds false) (typeof (AD_TRACKER) 'undefined' ...
Forbes.com - November 25, 2009 2:15 AM
* Says Bayer to pay 10 mln stg after UK approval of Sativex * Sees becoming commercial-stage pharma company in 2010 * FY pretax profit 1.2 mln stg vs 10.2 mln stg loss (Adds details) Nov 25 (Reuters) - Britain's GW Pharmaceuticals swung to its first ...
Reuters - November 25, 2009 2:09 AM
Pharma posts FY profit Reuters adsrc 'reuters.com.dart/bizfinance/markets/news/article;' ( typeof(AD_TRACKER) 'undefined' AD_TRACKER.globalAdSrcType null ) if Unleashed on Reuters Blogging the financial meltdown adsrc ...
